SVA — Sernova Biotherapeutics Balance Sheet
0.000.00%
Last trade - 00:00- CA$53.00m
- CA$57.51m
Annual balance sheet for Sernova Biotherapeutics, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | 2025 October 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 27.9 | 49.8 | 19.8 | 6.01 | 0.265 |
| Net Total Receivables | 0.449 | 1.15 | 1.05 | 0.298 | 0.123 |
| Prepaid Expenses | |||||
| Total Current Assets | 28.3 | 51.1 | 21 | 6.47 | 0.523 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.565 | 0.654 | 0.507 | 0.834 | 0.018 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 29.8 | 52.5 | 22.1 | 7.53 | 0.764 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.48 | 4.74 | 9.59 | 20 | 24.8 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 1.75 | 4.88 | 9.59 | 20.5 | 25.8 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 28.1 | 47.6 | 12.5 | -13 | -25.1 |
| Total Liabilities & Shareholders' Equity | 29.8 | 52.5 | 22.1 | 7.53 | 0.764 |
| Total Common Shares Outstanding |